PreEclampsia

Our Dedication to Women and Families

LifeAssay Diagnostics won two Grand Challenges Grants from the Bill and Melinda Gates Foundation to develop and commercialize a low-cost PrCr urine dipstick to combat the devastating effects of Preeclampsia in developing countries. 
 
The World Health Organization estimates that Preeclampsia/Eclampsia accounts for at least 16% of maternal deaths. Early identification of women at high risk for developing PE/E is key to linking them to proper health interventions to avoid complications and death.
 
The PrCr urine dipstick that has shown strong laboratory-based performance and high usability within ANC settings. 
 

To learn more about our clinical data:

To learn more about our collaboration with PATH:  

LifeAssay Diagnostics Test-it PrCr Urinalysis Dipstick Test

-

LifeAssay Diagnostics Test-itTM PrCr Urinalysis Dipstick Test

View PDF

Development of new diagnostic tools to improve preeclampsia screening

-

Development of new diagnostic tools to improve preeclampsia screening

View PDF

Instructions for use:

Estimate Proteinuria as follows: